

Literatur zum Beitrag von Volkmar Aderhold (Kerbe 2/2013):

Neuroleptika zwischen Nutzen und Schaden.

Ein Update zur Neuroleptika-Debatte

Baldessarini RJ, Viguera AC (1995) Neuroleptic withdrawal in schizophrenic patients. *Arch Gen Psychiatry* 52:189-192

Bola, J, Kao DT, Soydan H. (2011). Antipsychotic medication for early episode schizophrenia. *Cochrane Database of Systematic Reviews* CD006374.

De Hert M, Correll UC, Cohen D (2010): Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. *Schizophrenia Research* 117: 68-74

Faber G, Smid HGOM, Van Gool AR, Wiersma D, van den Bosch RJ (2011): The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. *European Psychiatry* 27(4):275-80

Fibiger, H. (2012). Psychiatry, the pharmaceutical industry, and the road to better therapeutics. *Schizophrenia Bulletin* 38: 649-50.

Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes

of the first treated episode of psychosis. *Arch Gen Psychiatry* 2011; 68:

609–16.

Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. *Arch Gen Psychiatry* 52:173-188

Harrow M, Jobe TH, Faull RN. (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. *Psychol Med* 42(10):2145-55.

Ho B-C, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Arch Gen Psychiatry* 68:128-137

- Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV (2013):** Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. *J Clin Psychiatry.* 74(1):10-8
- Kapur S, Zipursky R, Jones C, Remington G, Houle S. (2000)** Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *American Journal of Psychiatry* 2000;4:514–20.
- Kendall, T. (2011).** The rise and fall of the atypical antipsychotics. *British Journal of Psychiatry* 199: 266-68.
- Lancet Editorial (2011).** No mental health without physical health, 377:611
- Lepping, P. Sambhi RS, Whittington R, Lane S, Poole R. (2011).** Clinical relevance of findings in trials of antipsychotics: systematic review. *British Journal of Psychiatry* 198: 341-5.
- Leucht, S. Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a).** Second-generation versus first-generation antipsychotic drugs for schizophrenia. *Lancet* 373: 31-41.
- Leucht, S. Arbter D, Engel RR, Kissling W, Davis JM (2009b).** How effective are second-generation antipsychotic drugs? *Molecular Psychiatry* 14: 429-47.
- Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012):** Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 379(9831):2063-71.
- Llorca PM, Chereau I, Bayle FJ, Lancon C. (2002)** Tardive dyskinesias and antipsychotics: a review. *Eur Psychiatry.*17(3):129-38.
- Manu P, Correll CU, van Winkel R, Wampers M, De Hert M.(2012):** Prediabetes in patients treated with antipsychotic drugs. *J Clin Psychiatry.* 73(4):460-6.
- Marques TR, Arenovich T, Agid O, Sajejev G, Muthen B, Chen L, et al.** The different trajectories of antipsychotic response: antipsychotics versus placebo. *Psychol Med* 2011; 41: 1481–8.
- Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M.(2013):** Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. *Schizophr Bull.* 39(2):295-305.
- Morrison, A. Hutton P, Shiers D, Turkington D (2012).** Antipsychotics: Is it time to introduce patient choice? *British Journal of Psychiatry* 201: 83-4.
- Radua, J. Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (2012).** Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and

the effects of antipsychotic medication. *Neuroscience and Biobehavioral Reviews*. 36(10):2325-33

Remington G, Seeman P, Shammi C, Mann S, Kapur S (2005) „Extended“ antipsychotic dosing: rationale and pilot data. *J Clin Psychopharmacol*. 25:611-613

Remington G, Kapur S (2010) Antipsychotic dosing: how much but also how often? *Schizophr Bull* 36:900-903

Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S (2011) „Extended“ antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 72:1042-1048

Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H.(2012) Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. *Schizophr Bull*. 2012 Jan 30. [Epub ahead of print]

Samaha AN, Reckless GE, Seeman P, et al. (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. *Biol Psychiatry* 64:145–152

Seeman, M. (2011). Antipsychotics and physical attractiveness. *Clinical Schizophrenia and Related Psychoses* 5: 142-146C.

Spielmans, G. and Parry, P. (2010). From evidence-based medicine to marketing-based medicine. *Journal of Bioethical Inquiry* 7: 13-29.

Stahl SM, Mignon L, Meyer JM. (2009): Which comes first: atypical antipsychotic treatment or cardiometabolic risk? *Acta Psychiatr Scand*.119(3):171-9.

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka, T, Niskanen, L et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet*, 374 (9690): 620-7.

Tyrer, P. (2012). From the editor's desk. *British Journal of Psychiatry* 201: 168.

Viguera AC, Baldessarini RJ (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. *Arch Gen Psychiatry* 54:49-55

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollo (2009): The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. *Am J Psychiatry* 166(9):1055-62

Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. *Schizophr Res* 2009; 113: 1–11.

Zipursky RB, Reilly TJ, Murray RM.(2012): The Myth of Schizophrenia as a Progressive Brain Disease. *Schizophr Bull*. 2012 Dec 7. [Epub ahead of print]